The epidemiological backdrop underscores the urgency of this research: nearly 40 percent of adults in the United States suffer from obesity, and approximately one in three individuals over the age of 70 experience some form of age-related memory loss. Despite these staggering statistics, therapeutic interventions for memory decline remain limited, largely because the biological pathways driving these changes are not fully understood. Jarome’s laboratory explores whether obesity hastens the aging process in the brain, identifying common molecular signatures that might underlie both conditions.

Central to this investigation is a ubiquitin-dependent signaling modification known as K63 polyubiquitination. This post-translational modification regulates protein function and trafficking critical to synaptic plasticity during learning and memory formation. Intriguingly, Jarome’s previous work revealed that K63 polyubiquitination activity dysregulates with age: whereas in younger brains K63 levels dynamically decrease during learning to facilitate memory encoding, in older brains these levels remain abnormally elevated, suggesting a maladaptive failure to regulate synaptic function.

To probe causality, Jarome’s team employed gene-editing tools that selectively reduce K63 polyubiquitination. Remarkably, this intervention in aged rodent models restored memory performance, demonstrating that excessive K63 activity is not merely correlative but functionally contributory to memory impairments. This insight opened new avenues for targeting molecular processes that underpin cognitive decline, particularly those exacerbated by aging.

Expanding their focus, the researchers examined the effects of a high-fat diet on younger rats to model obesity-induced cognitive deficits. The outcomes were striking: obese rats exhibited elevated K63 polyubiquitination levels comparable to those in much older animals, coupled with significant memory impairments. These findings suggested that obesity may induce premature brain aging through the same molecular mechanisms observed in natural aging, effectively accelerating synaptic dysfunction and cognitive decline on a compressed timeline.

This unexpected convergence of molecular pathways implicated in both obesity and aging underscores the potential of K63 polyubiquitination as a unifying mechanism. If obesity-induced and age-related memory loss share this pathway, then targeting K63 regulation could represent a novel therapeutic strategy to mitigate the risk of dementia. This hypothesis promises a profound shift in how neurodegenerative risk factors are conceptualized and treated.

In Jarome’s forthcoming longitudinal study, young rats will be monitored from early adulthood through senescence while receiving either a standard or high-fat diet. This design aims to delineate temporal patterns of memory decline alongside dynamic changes in protein modification profiles. By employing precise CRISPR-based gene editing to reduce K63 levels before obesity onset, the team seeks to establish whether modifying this pathway can preempt or delay memory deficits linked to both excessive weight and aging.

The implications of this research extend far beyond rodent models. Molecular targets like K63 polyubiquitination could pioneer a new class of therapeutics designed to slow or prevent cognitive decline before irreversible neurodegeneration sets in. Such interventions would be transformative across aging populations worldwide, especially as obesity rates continue to climb and life expectancy lengthens.

Professor Jarome emphasizes the translational promise: “Understanding the mechanistic overlap between obesity and brain aging points us to specific biochemical targets. Our hope is to develop interventions that slow down this accelerated aging process, thereby reducing the prevalence and impact of dementia and Alzheimer’s disease.” His work exemplifies how dissecting fundamental molecular biology can reshape clinical strategies in neurology.

This synthesis of metabolic and neurobiological research highlights the importance of integrating diverse scientific domains to tackle complex diseases. The intersection of neuroscience, molecular biology, and metabolic health reveals novel insights into cognitive impairment’s etiology and opens pathways for multidisciplinary approaches to treatment and prevention.

As the research progresses, it invites a broader reevaluation of lifestyle and pharmacological guidelines for brain health. Targeting molecular aging signatures altered by obesity could complement current measures aimed at controlling weight and metabolic syndrome, providing a dual approach to preserve cognition across the lifespan.

With a significant grant from the National Institute on Aging fueling these investigations, Professor Jarome’s lab stands at the forefront of a new frontier. Unlocking the molecular crosstalk between obesity and neural aging may ultimately yield critical breakthroughs capable of delaying or preventing the devastating effects of memory loss disorders and neurodegeneration.

In summary, the emerging evidence from Jarome’s research underscores a pivotal connection rooted in K63 polyubiquitination — one that links the metabolic state induced by obesity with accelerated brain aging and memory decline. This discovery not only advances our understanding of dementia risk but also lays the groundwork for innovative therapeutic strategies aimed at preserving cognitive health in an aging and increasingly obese global population.

Subject of Research: Molecular mechanisms linking obesity to accelerated brain aging and memory decline

Article Title: Obesity Accelerates Brain Aging via Dysregulated K63 Polyubiquitination: Insights from Virginia Tech Neuroscience Research

News Publication Date: 2024

Web References:

• https://news.vt.edu/articles/2024/01/cals-jarome-SCHEV-award.html
• https://news.vt.edu/articles/2025/10/cals-jarome-improving-memory.html
• https://sas.vt.edu/people/faculty/jarome-timothy.html

Image Credits: Photo by Marya Barlow for Virginia Tech

Keywords: neurodegeneration, obesity, memory decline, K63 polyubiquitination, aging brain, dementia, Alzheimer’s disease, cognitive disorders, CRISPR gene editing, molecular neuroscience

CAR-T cell therapy, approved by the FDA in 2017 for certain blood cancers such as acute lymphoblastic leukemia, involves genetically modifying a patient’s own T cells to specifically target and destroy cancerous cells. The promise of this approach is underscored by impressive patient outcomes and long-term remissions, yet a subset of survivors report cognitive complaints, including impaired memory, difficulty concentrating, and a sense of mental cloudiness that has colloquially become known as "brain fog". Until now, the biological basis for these symptoms linked solely to immunotherapy was not clearly established.

In this pivotal study, the Stanford team, including senior author Dr. Michelle Monje, utilized advanced animal models to mimic CAR-T therapy in mice harboring tumors in various bodily compartments, including the brain, blood, skin, and bone. Remarkably, CAR-T treatment produced mild cognitive deficits irrespective of whether the tumors were located within or outside the brain, implying that immunotherapy-induced neuroinflammation does not require direct brain involvement. The only exception was mice with bone tumors that elicited minimal systemic inflammation, suggesting that the degree of immune activation influences the cognitive outcome.

Delving into the neurobiological mechanisms, the scientists identified microglia—the brain’s resident immune cells—as pivotal mediators in the development of cognitive dysfunction following CAR-T therapy. Upon therapy-induced systemic immune activation, microglia become chronically activated and begin secreting inflammatory molecules such as cytokines and chemokines. These proinflammatory signals adversely affect oligodendrocytes, the specialized glial cells responsible for synthesizing myelin sheaths that insulate neuronal axons. Loss of myelin integrity disrupts neural conduction efficiency, manifesting as cognitive impairment.

Supporting the translational relevance of their findings, postmortem brain tissue from human patients enrolled in an ongoing clinical trial of CAR-T therapy targeting brainstem and spinal cord tumors exhibited similar microglial activation and oligodendrocyte dysfunction patterns, mirroring those observed in the murine models. This cross-species consistency strengthens the hypothesis that immune-driven white matter injury underlies the cognitive sequelae seen in some cancer immunotherapy recipients.

Encouragingly, the Stanford researchers demonstrated that targeting the neuroimmune axis can reverse the cognitive impairments in mice. Temporary depletion of microglia using pharmacologic agents allowed for repopulation of these cells in a quiescent, non-inflammatory state, thereby restoring cognitive performance. Similarly, administering a drug capable of crossing the blood-brain barrier and selectively blocking chemokine receptor signaling effectively ameliorated cognitive deficits, highlighting a viable molecular target for therapeutic intervention.

The discovery of a unifying pathophysiological pathway that links immunotherapy-related brain fog with similar syndromes observed after chemotherapy and mild respiratory infections such as influenza and COVID-19 provides critical insight into a previously elusive phenomenon. These shared mechanisms emphasize the central role of neuroimmune interactions and myelin integrity in cognitive function, suggesting that interventions developed in this context may have broad applicability.

Dr. Monje emphasized the urgency of understanding such side effects in light of the growing use of CAR-T cell therapies and the importance of cognition for quality of life, especially in pediatric patients whose brains are still in development. Given that current therapies for brain fog remain limited, this research paves the way toward developing effective treatments that could enhance the recovery and daily functioning of cancer survivors.

The study also underscores the complexity of neuroimmune crosstalk, demonstrating that peripheral immune activation can have profound effects within the central nervous system without direct tumor involvement in the brain. This discovery challenges previous assumptions and calls for a reexamination of other immunotherapy regimens’ potential cognitive effects.

Collaborators from New York University’s Grossman School of Medicine and Washington University School of Medicine contributed expertise in immunology, neurobiology, and clinical oncology to this interdisciplinary effort. Funding support from prestigious institutions and foundations, including the Howard Hughes Medical Institute, National Cancer Institute, and others, reflects the significance attributed to this research.

On a broader scale, these findings compel the scientific and medical communities to monitor and address cognitive health proactively in patients undergoing cutting-edge cancer treatments. Furthermore, the identification of microglia and chemokine signaling as therapeutic targets may spur pharmaceutical innovation toward tailored therapies that mitigate neuroinflammation-induced cognitive impairment.

As research continues, ongoing clinical trials and translational studies will be instrumental in validating these interventions in human patients and refining treatment protocols to balance potent anti-cancer efficacy with preservation of cognitive function. The Stanford team’s work heralds a new chapter in understanding and managing the neurological side effects of cancer immunotherapy, with implications that may extend well beyond oncology.

Subject of Research: Animals

Article Title: Not specified in the provided content

News Publication Date: 12-May-2025

Image Credits: Emily Moskal/Stanford Medicine

Keywords: Cancer immunotherapy, Memory disorders